Reproductive health demands more than shortnterm fixes. Our fertility programs use biologics derived from young, healthy perinatal MSCs, standardized to deliver 40–50 billion exosomes per cc. These exosomes send regenerative signals that enhance ovarian response, embryo quality, and endometrial receptivity.
For women facing poor ovarian reserve, recurrent failed IVF cycles, or thin endometrial lining, our therapies offer a breakthrough alternative — giving new hope where traditional methods may fall short.